Munich - Delayed Quote EUR

Cassava Sciences Inc (PX91.MU)

2.2475

+0.0430

(+1.95%)

At close: December 20 at 9:55:00 PM GMT+1

Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More

SAVA and APLT tank on pipeline and regulatory setbacks.

Zacks 21 days ago

BBIO

APLT

SAVAW
A Post-Mortem on Cassava Sciences

This was a stock that traded above $140 a few short years ago. Now, it's all blown-up, leaving investors wondering why.

Zacks 24 days ago

SAVAW
SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study

Cassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline.

Zacks 24 days ago

SAVAW
Down -83.93% in 4 Weeks, Here's Why You Should You Buy the Dip in Cassava Sciences (SAVA)

Cassava Sciences (SAVA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks 24 days ago

SAVAW
Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops

Cassava Sciences stock plummeted Monday after the company's Alzheimer's treatment failed in Phase 3 testing.

Investor's Business Daily 25 days ago

SAVA

SAVAW
Cassava Sciences plummets over 80% on Alzheimer's trial fail

Cassava Sciences (SAVA) shares are cratering by over 80% on Monday after the pharmaceutical company failed to meet its latest phase three trial goals on its Alzheimer's treatment drug, simufilam. Yahoo Finance senior health reporter Anjalee Khemlani breaks down the story to Market Domination's Julie Hyman and Josh Lipton and what this all means for Cassava, especially as simufilam was its only drug in development at this time. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Luke Carberry Mogan.

Yahoo Finance Video 25 days ago

SAVA

SAVAW
Cassava Sciences stock plummets after Phase III Alzheimer’s fail

Following the ReThink study failure, Cassava Sciences is discontinuing the Phase III ReFocus trial and open-label study.

Clinical Trials Arena 25 days ago

SAVAW
Cassava Sciences update: SAVA stock price collapses after much-criticized Alzheimer’s drug flops

Shares in the pharmaceutical company fell a staggering 85% on Monday after it reported disappointing Phase 3 results, but its problems started way before that.

FastCompany 25 days ago

SAVAW
Cassava Sciences Stock Slides 84% as Alzheimer’s Trial Fails

The treatment didn’t show a significant reduction in cognitive or functional decline compared with a placebo.

Barrons.com 25 days ago

SAVAW
Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies

Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate Alzheimer’s disease. The trial did not meet the pre-specified co-primary, secondary, and exploratory biomarker endpoints. In July, CEO Rick Barry wrote a letter to shareholders and employees, saying that the company is in the final stages of testing simufilam and has significant financial and emotional stakes. The co-primary endpoint

Benzinga 25 days ago

SAVAW
Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study

Cassava Sciences shares are plunging in premarket trading and are losing most of their value after the biotech firm said its experimental Simufilam drug aimed at treating Alzheimer’s disease failed to show a “significant reduction in cognitive or functional decline” during the Phase 3 trial of the treatment.

Investopedia 25 days ago

SAVAW
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s disease in the ReThink-ALZ Phase 3 study Simufilam continued to demonstrate an overall favorable safety profile Cassava intends to present the data at an upcoming medical meeting The Company will hold a webcast today, November 25, 2024, at 8:00 AM ET AUSTIN, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Com

GlobeNewswire 25 days ago

SAVA

SAVAW
Cassava Sciences to Hold Corporate Update on November 25th

Webcast planned for Monday, November 25th at 8:00 AM ETAUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer’s disease, today announced it will hold a conference call and webcast on Monday, November 25th at 8:00 a.m. Eastern Time. Event Details: Date: Monday, November 25th Time: 8:00 a.m. Eastern Time Webcast: https://lifescievents.com/event/cassava/ A replay of the audi

GlobeNewswire 25 days ago

SAVA

SAVAW
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer

Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs Appointment initiates Cassava’s commercial readiness strategy as the Company prepares for first Phase 3 topline data readout before year end 2024 AUSTIN, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer’s disease, today announced the appointment of Fr

GlobeNewswire last month

SAVA

SAVAW
Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?

Here is how Cassava Sciences, Inc. (SAVA) and biote Corp. (BTMD) have performed compared to their sector so far this year.

Zacks last month

SAVAW
What Makes Cassava Sciences (SAVA) a New Buy Stock

Cassava Sciences (SAVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks last month

SAVAW
Cassava Sciences Reports Q3 2024 Financial and Operating Results

Top-line Data for RETHINK-ALZ 52-week Phase 3 trial Expected Before the End of 2024 $149.0 Million in Cash and Cash Equivalents at September 30, 2024. Expected To Support Operations Into 2026 Conference Webcast Scheduled for Today at 8:30AM ET AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer’s disease, today reported financial results for the third quarter ended Sep

GlobeNewswire last month

SAVA

SAVAW
Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

Conference call and webcast to begin at 8:30 AM ETAUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time. Event details: Date:Thursday, November 7thTime:8:30 a.m. Eastern TimeAudio Webcast:https://www.CassavaSciences.com/company-presentationsOrAudio Webcast:https://edge.media-server.com/mmc/

GlobeNewswire last month

SAVA

SAVAW
Institutions along with individual investors who hold considerable shares inCassava Sciences, Inc. (NASDAQ:SAVA) come under pressure; lose 6.7% of holdings value

Key Insights Cassava Sciences' significant individual investors ownership suggests that the key decisions are...

Simply Wall St. last month

SAVA

SAVAW
MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) stock is trading higher on Monday after the company released new preclinical findings from Ketamir-2, a novel oral ketamine analog. The new preclinical data show that Ketamir-2 is 60% more effective than the FDA-approved neuropathic pain treatment gabapentin in reducing chemotherapy-induced pain. The study used the paclitaxel (PTX) model, in which a common chemotherapy drug, PTX, was administered to mice to induce neuropathic pain. Also Read: MIRA Pharmac

Benzinga last month

MIRA

SAVAW

Performance Overview

Return	PX91.MU	S&P 500
YTD	-89.21%	+24.34%
1-Year	-91.48%	+24.38%
3-Year	-94.04%	+28.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cassava Sciences Inc (PX91.MU)

Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More

A Post-Mortem on Cassava Sciences

SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study

Down -83.93% in 4 Weeks, Here's Why You Should You Buy the Dip in Cassava Sciences (SAVA)

Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops

Cassava Sciences plummets over 80% on Alzheimer's trial fail

Cassava Sciences stock plummets after Phase III Alzheimer’s fail

Cassava Sciences update: SAVA stock price collapses after much-criticized Alzheimer’s drug flops

Cassava Sciences Stock Slides 84% as Alzheimer’s Trial Fails

Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies

Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

Cassava Sciences to Hold Corporate Update on November 25th

Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer

Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?

What Makes Cassava Sciences (SAVA) a New Buy Stock

Cassava Sciences Reports Q3 2024 Financial and Operating Results

Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

Institutions along with individual investors who hold considerable shares inCassava Sciences, Inc. (NASDAQ:SAVA) come under pressure; lose 6.7% of holdings value

MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain

Performance Overview